Who are Diclofenac oral + scopolamina oral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Diclofenac and Atropine combination drug.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diclofenac-oral-scopolamina-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Diclofenac oral + scopolamina oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diclofenac oral + scopolamina oral (Diclofenac oral + scopolamina oral) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + anticholinergic combination. Area: Pain management / Gastroenterology.

marketed NSAID + anticholinergic combination COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine) Pain management / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac oral + scopolamina oral (Diclofenac oral + scopolamina oral) — Hospital de Clinicas de Porto Alegre. This combination uses diclofenac to reduce pain and inflammation via COX inhibition, and scopolamine to reduce gastrointestinal motility and secretions, thereby decreasing nausea and cramping associated with the NSAID.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diclofenac oral + scopolamina oral TARGET	Diclofenac oral + scopolamina oral	Hospital de Clinicas de Porto Alegre	marketed	NSAID + anticholinergic combination	COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)
Diclofenac and Atropine combination drug	Diclofenac and Atropine combination drug	Brigham and Women's Hospital	phase 3	NSAID + Anticholinergic combination	COX-1/COX-2 (diclofenac); Muscarinic acetylcholine receptors (atropine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + anticholinergic combination class)

Hospital de Clinicas de Porto Alegre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac oral + scopolamina oral — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-oral-scopolamina-oral. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab